[MigVax and OurCrowd in Forbes] New Developments In Producing A COVID-19 Vaccine And Identifying High-Risk Individuals

Jerusalem-based OurCrowd announced today that it would lead a $ 12 million investment in the newly formed startup MigVax, an affiliate of The Migal Galilee Research Institute.

Read more here.

The post [MigVax and OurCrowd in Forbes] New Developments In Producing A COVID-19 Vaccine And Identifying High-Risk Individuals appeared first on OurCrowd.

OurCrowd

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *